A Guide to the Prescription and Service Request Form

Complete a Prescription and Service Request Form for each new patient and fax it to Teva Support Solutions® at 1-844-838-2213.

SERVICES REQUESTED

To initiate the full benefits offered by Teva Support Solutions®, check all the appropriate services.

PREFERRED ACQUISITION METHOD

This section should only be completed if CINQAIR® (reslizumab) Injection will be administered within the physician's office setting. Indicate the preferred method of product acquisition.

PATIENT INFORMATION

Patients will be contacted regarding their insurance coverage, financial assistance, and will receive ongoing nursing support and education.

INSURANCE INFORMATION

A Nurse Case Administrator will be assigned to verify benefits, parameter about Prior Authorization and will be available to answer any questions.

PRESCRIPTION INFORMATION

Record patient weight in kilograms and verify weight-based dosing calculation. Be sure to include Blood Eosinophil Count and test date.

ADMINISTRATION

Submit complete information about the site of administration if the patient will not receive the medication at the Prescribing Physician's Office.

PATIENT and PROVIDER AUTHORIZATION

Be sure to include valid patient and prescriber signatures and date. Prescriber must include NPI number.

Important Safety Information

WARNING: ANAPHYLAXIS

- Anaphylaxis has been observed with CINQAIR (reslizumab) infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR.
- Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis.

Please see additional Important Safety Information on back and enclosed full Prescribing Information, including Boxed WARNING for CINQAIR® (reslizumab) Injection.

ATIENT INFORMATION (Please you or print clearly) The First, ML tast, Sidnight: The First ML tast, Sidnight: T	ase complete form, sign, and	SERVICE REQUEST FOR fax to 1-844-838-2213 se call Teva Support Solutions® Monda	. IVI y-Friday, 9am-7pm EST at 1-844-838-2211	TEVA SUPPO SOLUTION	C F 131 C F
The clark Man (Last Suffice)	RVICES REQUESTED: ease check all that apply)			☐ Buy-and-Bill	·
Index places: Colif Prince Description Dug Allergies: Courter Medications:	ATIENT INFORMATION	N (Please type or print clearly)			
The Proces Col Pitcher	me (First, MI, Last, Suffix):			Date of Birth:	Gender: M □ F □
Display Allergoine Display Dis	me Address:		City:	State:	ZIP:
SUBLANCE INFORMATION Present complete or provide front and back copies of ALL insurance cardols D #: Group #: Phone #: Cord Name: D #: BN #: PON #: Group #: Phone #: Cord Name:	Home Phone:	Cell Phone:	(please check preferred phone n	umber) Email address:	
Thought Name: D #: Group #: Phone #:	Primary Language Spoken:	Curre	ent Medications:		
decider Name: D#: Bit #: PON #: Group #: Phone #: Conday Insurance: dicider Name: D#: Bit #: PON #: Group #: Phone #: dicider Name: D#: Group #: D#: Group #: Phone #: dicider Name: D#: Group #: D#: Group #: Phone #: dicider Name: D#: Group #: Phone #: dicider Name: D#: Group #: Phone #: dicider Name: D#: Group #: Phone #: D#: Group #: Phone #: dicider Name: D#: Group #: Phone #: D#: Group #: D#: Group #: Phone #: D#: Group #: Phone #: D#: Group #: D#: Group #: D#: D#: Group #: D#: D#: D#: D#: D#: D#: D#: D#: D#:	ISURANCE INFORM	ATION (Please complete or provide f	ront and back copies of ALL insurance cards)		
Card Name: D #: BN #: PCN #: Group #: condary Insurance: D #: Group #: Phone #:	mary Insurance:				
condary Insurance: Chicker Charles Charles Compared Com	dholder Name:		ID #:	Group #:	Phone #:
cholder Name: D #: Group #: Phone #: Isian: A B C C (Advantage) D Note: Specially Pharmacy acquisition not available for Medicare A & B	Card Name:	ID #:	BIN #:	PCN #:	Group #:
ACRESCRIBER INFORMATION Click Name: Tax ID: Contact Name: Fax: Tax ID: Contact Name: Name: Tax ID: Contact Name: Name: Name every 4 weeks: Tax ID: Contact Name: Na	condary Insurance:				
ACRESCRIBER INFORMATION Citico Name: Tax ID: Contact Name: Fax: Tax ID: Contact Name: Tax ID: Contact Name: Tax ID: Contact Name: Tax ID: Contact Name: Same a of Ingle in Instance on In	dholder Name:		ID #:	Group #:	Phone #:
RESCRIBER INFORMATION Citico Name: Tax D: City: State: ZP: Contact Name: Fax: Title: Ti	dicare: A 🗆 B 🗅 C 🖵 (Adv	rantage) D Note: Specialty Pharm	nacy acquisition not available for Medicare A & B		
Scriber Name: Tax ID: Clay: State: ZIP: Fax: Title: Title:					
Figure 1. State: ZIP: Pack Pack	ctice Name:				
Fax: Title: Fax: Title: Fax: Fax:	scriber Name:		Tax ID:		
Fax: Title: Fax:	ctice Mailing Address:		City:	State:	ZIP:
Fax: Fax: F	ne:		Fax:		
RIPTIO Top To	Contact Name			Title:	
Blood Eosinophil Count:	mg/10 r g/kg in ously ght-Ba Dosir culat	every 4 weeks in 50 of sterile 0.9% ion: Patient weight X 3 mg = # of	mg to infuse every 4 weeks		Dofill. Him
In the presentation of the		_ kg Illiuse:Ilig			
of Administration: Prescribing Physician's Office Mon-Prescribing Physician's Office Mon-Prescribing Physician's Practice above, please complete the following: ne of Preferred Infusion Center: tack Name: Phone: Fax: NPI #: tack Name: Phone: Fax: NPI #: tress: City: State: ZIP: ATTENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION brotze each of my healthcare provider(s) and my health insurer(s) to use and disclose my protected health information (PH) related to: my medical condition and treatment, my health insurance and payment/benefits information, services provided, and my demographic and contact information to Patient Services and Solutions, Inc. (Id/ha "Tea-Support Soutions" and "Shared Solutions Pharmacy" (collectively referred to as the Program) and its affiliates, its and representations; including, but not limited to any third party financial assistance, or the purposes destinates; individing, but not limited to any third party financial assistance; for the purpose of the Authorization is (i) to provide therapy apport off) to provide the party financial assistance; for the purpose of the Authorization is a provided, and program and contact me by male, email, text message or by live, audicidate and/or prescorded messages at the telephone number (s) islated above, or to any and any off in the financial consistance of the purpose of the Authorization is (i) to provide the reapy apport (iii) to provide the prescription benefits investigation and coordinate prescription fulfilliment and financial assistance; (iv) for marketing are and vily for marketing provided by my employed with includes contacting me to participate in toous groups, surveys or interviews. The Program will safeguard my information and only use it for intended purposes, Lunderstand that once my health information is disclosed it may be re-disclosed by the Program and other recipients and no longe to protected exical plants, live in the authorization will repair to the part of the Edical plants on the distance of th			Biood Eosinophii Count.		lest Date
deministration site has a different address than the Prescribing Physician's Practice above, please complete the following: the of Preferred Infusion Center: tact Name: Phone: Fax: NPI #: Tress: City: State: ZiP: ATTIENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION brotree earth of my health care provider(s) and my health insurer(s) to use and disclose my protected health information (PH) related to: my medical condition and treatment, my health insurer (so the services provided, and my demographic and contact information to Patient Services and Solutions, inc. (driv's "Teas Support Soutions" and "Stated Soutions Pharmacy" (collectively referred to as the Program) and its affiliates, its and representatives, including, but not limited to any third party financial assistance; for the purposes described below. Lestant that the purpose of this Authorization is (i) to erroll me in the Program and contact me by mall, email, text message or by live, audicided and/or precorded messages at the belightone number (s) listed above, or to any the submitted to any third provided length system (s) for marketing sorted by the program and contact me by mall, email, text message or by live, audicided and/or precorded messages at the belightone number (s) listed and (w) for marketing sorted by my included and provided treating in fill the submitted in consideration and control and the program and contact messages at the belightone number (s) listed and (w) for marketing sorted by the program and other recipients and no longer be protected decised privacy law. This authorization will remain in effect until the Program ends. I understand that once my health information is disclosed it may be re-disclosed by the Program and other recipients and no longer be protected decised privacy law. This authorization will remain in effect until the Program ends. I understand that once my health information is disclosed it may be re-disclosed by the Program and other recipients and no longer be protected decised privac		sing Dhugiaiania Office. D Non Drocaril	ing Physician's Office D Hespital Cutactions D C	Whav.	
Tack Name: Phone: Fax: NPI#: Tack Name: Phone: Fax: NPI#: TIENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION To use and only healthcare provider(s) and my health insurer(s) to use and disclose my protected health information (PHI) related to my medical condition and treatment, my health insurance and payment/benefits information. Services provided, and my demographic and contact information to Patient's Services and Solutions, Inc. (Id/ha' Ties-Support Solutions' and "Stared Solutions Pharmary" (collectively referred to as the Program) and its affiliates is and representatives, including, but not limited to any third party financial assistance administration, or the purposes destricts including that not illimited to any third party financial assistance administration, or the purpose destroched below. Senstand that the purpose of this Authorization is: (i) to enroll me in the Program and contact me by mail, email, text message or by live, autodiaed and/or prescorded messages at the telephone number(s) listed above, or to any elegistration number(s) provided by me (ii) to provide the heapy support (iii) to conduct benefits investigation and condribate in himmatical assistance; (ii) for market research purposes which includes unprocess understances and only use the understance of the Program and early (iii) for market research purposes which includes unprocess understances and only use the understance of the Program and any view set the research purposes which includes contacting me to participate in focus groups, surveys or iteratives and services settled to my thereign or my reduced certain process. Understand the program and or dry use it for intended purposes, understances and solutions process. Interviews. In a provided the program and or dry use it for intended purposes, understances and solutions, line. After Privage Office, P.O. Box 7588		· ,	* ,		
tact Name: Phone: Fax: NPI #: Files: City: State: ZIP: ***TIENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION Those each of my health care providerig) and my health insurance and pagment/benefits information, benefices provided, and my demographic and contact information to Patient Services and Solutions, Inc. (id b'a "Tien Support Solutions" and "Shared Solutions or Premazy" (collectively referred to as the Program)) and its affiliates, its and representables, including, but not limited to any third party financial assistance administrators, to the purposes described beard condition and resument, my health insurance and pagment/benefits information previouse provided, and my demographic and contact information to Patient Services and Solutions; in the program shall result in the program and in the Program and orbact me by rample, example, example, but snot limited by my founding me with exclandational and promotional materials, information, special offers and services related prescription infolliment and financial assistance; (i) for marketing assistance by the program and under prescription infolliment and infancial assistance; (i) for marketing assistance provided by me (ii) to provide me with exclandational and promotional materials, information special offers and services related prescription infolliment and infancial assistance; (ii) for marketing assistance provided assistance; (ii) for marketing assistance proposes which includes contacting me to participate in flows; groups, surveys or interviews. **Example of the Program will assign a propose which includes contacting me to participate in flows; groups, surveys or interviews. **Example of the Program and other recipients and no longer be protected deel privacy law. This authorization will remain in effect, until the Program ends. Lunderstand that Imay revoke this authorization at any time, in writing sent to Patient Services and Solutions, Inc., Athr. Privacy Officer, P.O. Dos. 7588. ***Patient's Signature*** **Date** **Date**			rilysician's riactice above, piease complete i	ne following.	
City: State: ZIP: ATTENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION horder each of my health care providerig and my health insurerie; to use and disclose my protected relamit information (PHT) related to my medical condition and treatment, my health insurance and payment/benefits information, environmentary and my demographic and contact information in Defatrle Technica and Subtractions. (ii) (the Virance Support Southors' and "Shared Southors Pharmacy" (collectively referred to as the Program) and its affiliates, sets and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Its and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Its and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Its and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Its and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Its and representatives, but not limited to, providing me with exclusional and only use in in the Program and contract me by a Program also and via to a state of the present purposes within includes contacting me to participate in locus groups, surveys or interviews. The Program will assignation may information and only use it for intended purposes. Indicasting me to participate in locus groups, surveys or interviews. The Program will assignate my information and only use it for intended purposes. Indicastion and interviews and severe resident and only the respirators and only only the Program and other recipients and no longe the protected declar privacy law. This authorization will represent the current to the program and other recipients and no longe to the recipients and		•	Dhana	Ferr	NDI #-
ATTENT AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION horize earl of my healthcare provider(s) and my health insurer(s) to use and disclose my protected health information (PH) related to: my medical condition and treatment, my health insurance and payment/benefits information, and my demographic and contract information to Platest Services provided, (Wh's "Ties Support Soutions" and "Shared Soutions Pharmacy" (collectively referred to as the Program) and its affiliates, this and representatives, including, but not limited to any third party financial assistance administrators, for the purposes described below. Jesterath that the purpose of this Authorization is (i) to enroll the mine in the Program and contact mel by maje, read, less themses, or by live, autofield and/or prescorded messages at the telephone number(s) listed above, or to any telephone number(s) provided by me (ii) to provide therapy support (iii) to conduct benefits investigation and condribate my insurance coverage (iv) to coordinate prescription fulfillment and financial assistance; (ii) for marketing to be subjected to the property may be used to providing me with excutational and promotional materials, information, special offers and services related to my therapy or my medical condition which may be funded or sent by a Program attended to the Program will additionate the excutational and only use it for intended purposes. Indestruction and only use it in trended purposes, understand that come my health information is disclosed by the Program and other excipients and no longs to protected scheding lives (in the Program and other excipients and no longs to protected scheding lives (in the Program and other excipients and no longs to protected scheding lives (in the Program excitation will reproduce the adversary time and the control of the program of the program of the program and other excipients and only to the device and positions, inc. Alther Privacy Office, P.O. Bix 7888 and protected that the privace and device and p					
notice each of my healthcare providerity and my health insurers(s) to use and disclose my protected health information (PHT) related to my medical condition and reatment, my health insurance and pagment/benefits information, so reviews provided, and my demographic and contact information to Patient Services and Solutions, inc. (bit his "Ties Support Solutions" and "Strated Solutions Pharmacy" (collectively referred to as the Program) and its affiliates, is and representables, including, but not limited to any third party financial assistance; administrators, for the purposes described below. Interest of that the purpose of this Authorization is (i) to erroll me in the Program and contact me by mail, email, text message or by live, subdiciled and/or prerecorded messages at the telephone number(s) listed above, or to any telephone number (s) listed above, or to any insurance coverage (iv) to coordinate prescription fulfilliment and infrancial assistance; (ii) or marketing assess which includes contacting me to participate in house groups, surely entirely insurance coverage (iv) to coordinate prescription fulfilliment and infrancial assistance; (ii) or marketing assess which includes contacting me to participate in house groups, surely entirely insurance coverage (iv) to coordinate prescription fulfilliment and infrancial assistance; (iv) or marketing and only (iv) marketing in visuance overage with includes contacting me to participate in house groups, surely entirely insurance or my medical condition which may be funded or sent by a Program and only for marketing and entire five terms of the program and only to market mean the first until the Program ents. Lineated purposes, Lunderstand that once my health information is disclosed it may be re-disclosed by the Program and other recipients and no longs to program and other recipients a		TION TO LICE AND DICCLO			ZIP!
Patient's Signature Date pred by someone other than patient, describe legal authority to do so: RESCRIBER SIGNATURE REQUIRED thorize Patient Services and Solutions, Inc. to provide any information on this form to the insurer of the named patient and to forward the above prescription, by fax or by other mode of delivery ne patient and on the care chosen by the named patient. If this prescription is being shipped by the pharmacy to my office for administration, I agree to accept the medication on behalf of above named patient. Prescriber's Signature* Dispense as written Brand Exchange Permissible Date	thorize each of my healthcare provid services provided, and my demogra- tist and representatives, including, b dierstand that the purpose of this Au- te teleptone number(s) provided by to soses which includes, but is not limit ate and (vi) for market research pur- let the Program will safeguard my in elderal privacy law. This authorization fand Park, KS 66207, but that this ir	er(s) and my health insure(s) to use and disclo- phin and contact information to Patient Services, in orth limited to any third party firancial assists horization is (i) to enroll me in the Program at me me (ii) to provide hereapy support (ii) to condu- ent to, providing me with educational and promo posses which includes contacting me to particip formation and only use if for intended purposes will remain in effect until the Program ends. I use occasion will only solve for me health con-	se my protected health information (PHT) related to mny met is and Solutions, Inc., (du/ba "Ties Support Solutions" and "SI nice administratus, for the purposes described below. do contact me by mail, email, Lext message or by live, autodic to benefits innesightion and coordinate my insurance oxene- tional materials, information, special offers and services relat and in focus groups, surveys or interviews. I, Lunderstand that once my health information is disclosed it nderstand that once my health information is disclosed it	icial condition and treatment, my health in arred Solutions Pharmacy ⁷ (collectively n led and/or prerecorded messages at the je fly to coordinate prescription fulfillime ed to my therapy or my medical condition may be re-disclosed by the Program and writing sent to Patient Services and Solution my revocation and only to the event that	eferred to as the Programi) and its affiliates, telephone number(s) listed above, or to any at and financial assistance; (v) for marketing a which may be funded or sent by a Program of their recipients and no longer be protected ons, Inc., Atth: Privacy Officer, P.O. Box 7588, they have not affead taken action based on
RESCRIBER SIGNATURE REQUIRED Ithorize Patient Services and Solutions, Inc. to provide any information on this form to the insurer of the named patient and to forward the above prescription, by fax or by other mode of delivery he pharmacy and site of care chosen by the named patient. If this prescription is being shipped by the pharmacy to my office for administration, I agree to accept the medication on behalf of above named patient. Prescriber's Signature* Dispense as written Brand Exchange Permissible Date	Patient's Signature		and a payment of a caurion, a science canoning, engioni	но нашино волона, аз итезе al 6 ного	
thorize Patient Services and Solutions, Inc. to provide any information on this form to the insurer of the named patient and to forward the above prescription, by fax or by other mode of delivery ne pharmacy and site of care chosen by the named patient. If this prescription is being shipped by the pharmacy to my office for administration, I agree to accept the medication on behalf of above named patient. Prescriber's Signature* Dispense as written Brand Exchange Permissible Date	-				
Prescriber's Signature * Dispense as written Brand Exchange Permissible Date		lutions, Inc. to provide any information of			
	he pharmacy and site of care c				
	the pharmacy and site of care c above named patient. Prescriber's				



CINQAIR® (reslizumab) Injection

Indications and Usage

CINQAIR (reslizumab) Injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Limitations of Use: CINQAIR is **not** indicated for:

- treatment of other eosinophilic conditions
- relief of acute bronchospasm or status asthmaticus

Important Safety Information

WARNING: ANAPHYLAXIS

- Anaphylaxis has been observed with CINQAIR (reslizumab) infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR.
- Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis.

CONTRAINDICATIONS

• CINQAIR is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients.

WARNINGS AND PRECAUTIONS

- Acute Asthma Symptoms or Deteriorating Disease: CINQAIR should not be used to treat acute asthma symptoms or acute exacerbations. Do not use CINQAIR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with CINQAIR.
- Malignancy: In placebo-controlled clinical studies, 6/1028 (0.6%) patients receiving 3 mg/kg CINQAIR had at least 1 malignant neoplasm reported compared to 2/730 (0.3%) patients in the placebo group. The observed malignancies in CINQAIR-treated patients were diverse in nature and without clustering of any particular tissue type. The majority of malignancies were diagnosed within less than six months of exposure to CINQAIR.

- Reduction of Corticosteroid Dosage: No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of CINQAIR. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with CINQAIR. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
- Parasitic (Helminth) Infection: Eosinophils may be involved in the immunological response to some helminth infections. Treat patients with pre-existing helminth infections before initiating CINQAIR. If patients become infected while receiving treatment with CINQAIR and do not respond to anti-helminth treatment, discontinue treatment with CINQAIR until infection resolves.

ADVERSE REACTIONS

- Adverse reactions that occurred at ≥2% incidence and more commonly than in the placebo group included 1 event: oropharyngeal pain (2.6% vs. 2.2%).
- Elevated baseline creatine phosphokinase (CPK) was more frequent in patients randomized to CINQAIR (14%) versus placebo (9%). Transient CPK elevations in patients with normal baseline CPK values were observed more frequently with CINQAIR (20%) versus placebo (18%) during routine laboratory assessments.
- Myalgia was reported in 1% (10/1028) of patients in the CINQAIR 3 mg/kg group compared to 0.5% (4/730) of patients in the placebo group.
- Immunogenicity: In placebo-controlled studies, a treatment-emergent anti-reslizumab antibody response developed in 53/983 (5.4%) of CINQAIR-treated patients (3 mg/kg). The antibody responses were of low titer and often transient. There was no detectable impact of the antibodies on the clinical pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of CINQAIR.

